Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema

NCT04991350 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Insufficient recruitment

Conditions

Diabetic Macular Edema
Macular Ischemia
Diabetic Retinopathy
Vascular Endothelial Growth Factor Overexpression

Interventions

DRUG: Intravitreal ranibizumab
DRUG: Intravitreal bevacizumab

Sponsor

Cairo University